Eagle Pharmaceuticals, Inc. (EGRX)
USD 1.7
(13.0%)
USD 1.7
(13.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 7.14 Million USD | 109.92% |
| 2021 | -72.05 Million USD | -9.07% |
| 2020 | -66.06 Million USD | 7.24% |
| 2019 | -71.21 Million USD | -107.11% |
| 2018 | -34.38 Million USD | 48.58% |
| 2017 | -66.87 Million USD | -26.61% |
| 2016 | -52.82 Million USD | 33.21% |
| 2015 | -79.08 Million USD | -248.05% |
| 2014 | -22.72 Million USD | -117.32% |
| 2013 | -10.45 Million USD | -398.31% |
| 2012 | 3.5 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | 54.83 Million USD | 0.75% |
| 2023 Q1 | 54.43 Million USD | 661.82% |
| 2022 Q4 | 7.14 Million USD | -84.47% |
| 2022 Q2 | 17.03 Million USD | 140.65% |
| 2022 Q3 | 46 Million USD | 170.14% |
| 2022 FY | 7.14 Million USD | 109.92% |
| 2022 Q1 | -41.89 Million USD | 41.85% |
| 2021 Q4 | -72.05 Million USD | -5.95% |
| 2021 Q1 | -69.16 Million USD | -4.7% |
| 2021 FY | -72.05 Million USD | -9.07% |
| 2021 Q3 | -68 Million USD | 9.1% |
| 2021 Q2 | -74.81 Million USD | -8.17% |
| 2020 Q3 | -50.7 Million USD | 25.27% |
| 2020 Q1 | -50.51 Million USD | 29.07% |
| 2020 Q2 | -67.84 Million USD | -34.31% |
| 2020 Q4 | -66.06 Million USD | -30.29% |
| 2020 FY | -66.06 Million USD | 7.24% |
| 2019 Q3 | -77.52 Million USD | -19.87% |
| 2019 FY | -71.21 Million USD | -107.11% |
| 2019 Q4 | -71.21 Million USD | 8.13% |
| 2019 Q2 | -64.67 Million USD | -7.54% |
| 2019 Q1 | -60.14 Million USD | -74.9% |
| 2018 Q2 | -53.52 Million USD | -11.99% |
| 2018 Q1 | -47.79 Million USD | 28.53% |
| 2018 FY | -34.38 Million USD | 48.58% |
| 2018 Q4 | -34.38 Million USD | 26.7% |
| 2018 Q3 | -46.91 Million USD | 12.36% |
| 2017 Q1 | -27.71 Million USD | 47.54% |
| 2017 Q2 | -55.38 Million USD | -99.87% |
| 2017 Q3 | -48.6 Million USD | 12.23% |
| 2017 Q4 | -66.87 Million USD | -37.58% |
| 2017 FY | -66.87 Million USD | -26.61% |
| 2016 Q2 | -75.56 Million USD | 3.48% |
| 2016 FY | -52.82 Million USD | 33.21% |
| 2016 Q3 | -59.31 Million USD | 21.51% |
| 2016 Q4 | -52.82 Million USD | 10.94% |
| 2016 Q1 | -78.28 Million USD | 1.01% |
| 2015 Q2 | -13.68 Million USD | 86.3% |
| 2015 Q4 | -79.08 Million USD | -9.87% |
| 2015 Q3 | -71.97 Million USD | -425.93% |
| 2015 Q1 | -99.92 Million USD | -186.57% |
| 2015 FY | -79.08 Million USD | -248.05% |
| 2014 Q4 | -34.86 Million USD | -53.46% |
| 2014 Q1 | -54.87 Million USD | -450.21% |
| 2014 FY | -22.72 Million USD | -117.32% |
| 2014 Q2 | -49.79 Million USD | 9.27% |
| 2014 Q3 | -22.72 Million USD | 54.37% |
| 2013 Q2 | -10.8 Million USD | 0.0% |
| 2013 Q3 | -10.45 Million USD | 3.2% |
| 2013 FY | -10.45 Million USD | -398.31% |
| 2013 Q4 | -9.97 Million USD | 4.6% |
| 2012 Q4 | 6.56 Million USD | 229.6% |
| 2012 FY | 3.5 Million USD | 0.0% |
| 2012 Q3 | -5.06 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 92.416% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 90.467% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 98.359% |
| Cosmos Health Inc. | 8.59 Million USD | 16.829% |
| Dynavax Technologies Corporation | 106.63 Million USD | 93.3% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 105.461% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 98.349% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 145.7% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 145.7% |
| SCYNEXIS, Inc. | -19.35 Million USD | 136.925% |
| Safety Shot Inc | -2.28 Million USD | 412.777% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 175.771% |
| Alpha Teknova, Inc. | 1.97 Million USD | -261.955% |
| Bright Green Corporation | 1.84 Million USD | -287.952% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 98.442% |
| Embecta Corp. | 1.31 Billion USD | 99.455% |
| PainReform Ltd. | -7.95 Million USD | 189.874% |
| Journey Medical Corporation | -9.7 Million USD | 173.592% |
| Procaps Group, S.A. | 242.93 Million USD | 97.059% |
| Theratechnologies Inc. | 24.87 Million USD | 71.272% |
| Harrow Health, Inc. | 116.41 Million USD | 93.863% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 383.532% |
| Biofrontera Inc. | 4.05 Million USD | -76.159% |
| DURECT Corporation | -7.65 Million USD | 193.35% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 121.311% |
| Cronos Group Inc. | -663.32 Million USD | 101.077% |
| OptiNose, Inc. | 58.06 Million USD | 87.695% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 98.854% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 149.032% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 237.774% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 52.408% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 212.349% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -6586.381% |
| Radius Health, Inc. | 359.28 Million USD | 98.011% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -3523.06% |
| ProPhase Labs, Inc. | 19.23 Million USD | 62.846% |
| Phibro Animal Health Corporation | 454.84 Million USD | 98.429% |
| Procaps Group S.A. | 242.93 Million USD | 97.059% |
| Alvotech | 1.06 Billion USD | 99.329% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -94.263% |
| Viatris Inc. | 17.13 Billion USD | 99.958% |
| Rockwell Medical, Inc. | 4.45 Million USD | -60.346% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 246.504% |
| SIGA Technologies, Inc. | -148.68 Million USD | 104.806% |
| Tilray Brands, Inc. | 158.97 Million USD | 95.506% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 94.139% |
| Shineco, Inc. | 29.29 Million USD | 75.606% |
| PetIQ, Inc. | 351.93 Million USD | 97.97% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 346.258% |
| Incannex Healthcare Limited | -5.48 Million USD | 230.264% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 95.97% |
| Alimera Sciences, Inc. | 55.3 Million USD | 87.082% |
| Silver Spike Investment Corp. | -32.61 Million USD | 121.909% |
| Assertio Holdings, Inc. | -32.52 Million USD | 121.965% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 579.942% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 241.195% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 248.421% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 186.991% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -69.433% |
| Hempacco Co., Inc. | 13.61 Million USD | 47.52% |
| Talphera, Inc. | -5.72 Million USD | 224.891% |
| Alvotech | 1.06 Billion USD | 99.329% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 107.388% |
| Currenc Group, Inc. | -16.57 Million USD | 143.112% |
| Kamada Ltd. | -46.43 Million USD | 115.388% |
| Indivior PLC | -33.95 Million USD | 121.044% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -2642.023% |
| Flora Growth Corp. | -713 Thousand USD | 1102.104% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 186.991% |
| Evolus, Inc. | 63.7 Million USD | 88.785% |
| HUTCHMED (China) Limited | -197.45 Million USD | 103.618% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 98.509% |
| Akanda Corp. | 3.9 Million USD | -82.974% |